Termine
Performance
26.11.2021

19.11.21 Gesco AG
Veröffentlichung Quartalsmitteilung (Stichtag Q3)
19.11.21 Instone Real Estate Group SE
Roadshow
18.11.21 ABOUT YOU Holding SE
Analystenveranstaltung
18.11.21 Amphastar Pharmaceuticals, Inc.
Analysts' Conference
18.11.21 Global Fashion Group S.A.
Analysts' Conference
18.11.21 Gambling.com Group
Featured Event
18.11.21 2G Energy AG
Pressemeldung zur Quartalsmitteilung (Stichtag Q3)
18.11.21 Siemens Energy AG
Roadshow
18.11.21 Energy Recovery
Analysts' Conference
18.11.21 APONTIS PHARMA AG
Veröffentlichung Quartalsmitteilung (Stichtag Q3)
18.11.21 Instone Real Estate Group SE
Pressemeldung zur Quartalsmitteilung (Stichtag Q3)
18.11.21 Helmerich & Payne
Analysts' Conference
18.11.21 KWS SAAT SE & Co. KGaA
Veröffentlichung Quartalsmitteilung (Stichtag Q1)
18.11.21 Francotyp-Postalia Holding AG
Veröffentlichung Quartalsfinanzbericht (Stichtag Q3)
18.11.21 Einhell Germany AG
Veröffentlichung Quartalsmitteilung (Stichtag Q3)
18.11.21 thyssenkrupp AG
Veröffentlichung Jahresfinanzbericht
18.11.21 thyssenkrupp AG
Bilanzpressekonferenz
18.11.21 thyssenkrupp AG
Telefonkonferenz
18.11.21 Multitude SE
Veröffentlichung Quartalsfinanzbericht (Stichtag Q3)
18.11.21 IVU Traffic Technologies AG
Veröffentlichung Quartalsmitteilung (Stichtag Q3)

November

KW M D M D F S S
44 1 2 3 4 5 6 7
45 8 9 10 11 12 13 14
46 15 16 17 18 19 20 21
47 22 23 24 25 26 27 28
48 29 30          

Dezember

KW M D M D F S S
48     1 2 3 4 5
49 6 7 8 9 10 11 12
50 13 14 15 16 17 18 19
51 20 21 22 23 24 25 26
52 27 28 29 30 31    

Januar 2022

KW M D M D F S S
52           1 2
1 3 4 5 6 7 8 9
2 10 11 12 13 14 15 16
3 17 18 19 20 21 22 23
4 24 25 26 27 28 29 30
5 31            

 

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021